Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “antagonist”

678 pharma patents match "antagonist" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 678
Index total 30,257
Page 13 / 29

Quick answer

This filtered view shows 678 pharmaceutical patents matching "antagonist" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

678 results for “antagonist” · 30,257 patents in full index Clear search

  1. US 9339528

    Methods for treating epithelium trauma of the intestinal mucosa using interleukin-1 receptor antagonist

    GENERAL REGENERATIVES, LTD. · Granted May 17, 2016 · Expires May 12, 2036

    granted

  2. US 9334495

    Minor groove binder (MGB)-oligonucleotide miRNA antagonists

    ELITECHGROUP B.V. · Granted May 10, 2016 · Expires May 5, 2036

    granted

  3. US 9315463

    Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

    Almirall, S.A. · Granted Apr 19, 2016 · Expires Apr 14, 2036

    granted

  4. US 9315568

    Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders

    ADHERON THERAPEUTICS, INC. · Granted Apr 19, 2016 · Expires Apr 14, 2036

    granted

  5. US 9303258

    Method and compositions comprising small RNA agonist and antagonists to modulate inflammation

    The Regents of the University of California · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  6. US 9302120

    Spiro-oxindole MDM2 antagonists

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  7. US 9303045

    5-HT3 receptor antagonists

    Takeda Pharmaceutical Company Limited · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  8. US 9283220

    Compositions of opioid antagonists and methods for treating conditions caused by the varicella-zoster virus therewith

    IMUNEKS FARMA ILAC SANAYI VE TICARET ANONIM SIRKETI PAK IS MERKEZI · Granted Mar 15, 2016 · Expires Mar 10, 2036

    granted

  9. US 9283183

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Mar 15, 2016 · Expires Mar 10, 2036

    granted

  10. US 9277748

    Agonist/antagonist compositions and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 8, 2016 · Expires Mar 3, 2036

    granted

  11. US 9273093

    α4β7 peptide dimer antagonists

    Protagonist Therapeutics, Inc. · Granted Mar 1, 2016 · Expires Feb 25, 2036

    granted

  12. US 9272990

    Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis

    AMIRA PHARMACEUTICALS, INC. · Granted Mar 1, 2016 · Expires Feb 25, 2036

    granted

  13. US 9260504

    N- and C-terminal substituted antagonistic analogs of GH-RH

    THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Feb 16, 2016 · Expires Feb 11, 2036

    granted

  14. US 9254338

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 9, 2016 · Expires Feb 4, 2036

    granted

  15. US 9233162

    High affinity VEGF-receptor antagonists

    The Board of Regents of the University of Texas System · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted

  16. US 9233108

    Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

    Almirall, S.A. · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted

  17. US 9216971

    Quaternary ammonium compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Dec 22, 2015 · Expires Dec 17, 2035

    granted

  18. US 9206154

    Inverse agonists and neutral antagonists for the TSH receptor

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 8, 2015 · Expires Dec 3, 2035

    granted

  19. US 9206172

    8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Dec 8, 2015 · Expires Dec 3, 2035

    granted

  20. US 9199993

    8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Dec 1, 2015 · Expires Nov 26, 2035

    granted

  21. US 9193790

    Use of antagonists of the interaction between HIV GP120 and A4B7 integrin

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 24, 2015 · Expires Nov 19, 2035

    granted

  22. US 9181253

    Adenosine receptor agonists, partial agonists, and antagonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 10, 2015 · Expires Nov 5, 2035

    granted

  23. US 9156829

    Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists

    Takeda Pharmaceutical Company Limited · Granted Oct 13, 2015 · Expires Oct 8, 2035

    granted

  24. US 9133127

    Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

    Jenrin Discovery, LLC · Granted Sep 15, 2015 · Expires Sep 10, 2035

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.